|
1
|
Horowitz M, Neeman E, Sharon E and
Ben-Eliyahu S: Exploiting the critical perioperative period to
improve long-term cancer outcomes. Nat Rev Clin Oncol. 12:213–226.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng X, Zhang H, Hamad A, Huang H and
Tsung A: Surgery-mediated tumor-promoting effects on the immune
microenvironment. Semin Cancer Biol. 86:408–419. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bezu L, Akçal Öksüz D, Bell M, Buggy D,
Diaz-Cambronero O, Enlund M, Forget P, Gupta A, Hollmann MW,
Ionescu D, et al: Perioperative immunosuppressive factors during
cancer surgery: An updated review. Cancers (Basel). 16:23042024.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang F, Hua Q, Zhu X and Xu P: Surgical
stress induced tumor immune suppressive environment.
Carcinogenesis. 45:185–198. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim R: Effects of surgery and anesthetic
choice on immunosuppression and cancer recurrence. J Transl Med.
16:82018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Onuma AE, Zhang H, Gil L, Huang H and
Tsung A: Surgical stress promotes tumor progression: A focus on the
impact of the immune response. J Clin Med. 9:40962020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramly MS and Buggy DJ: Anesthetic
techniques and cancer outcomes: what is the current evidence?
Anesth Analg. 140:768–777. 2025. View Article : Google Scholar
|
|
8
|
Brogi E and Forfori F: Anesthesia and
cancer recurrence: An overview. J Anesth Analg Crit Care. 2:332022.
View Article : Google Scholar
|
|
9
|
Xia SH, Zhou D, Ge F, Sun M, Chen X, Zhang
H and Miao C: Influence of perioperative anesthesia on cancer
recurrence: from basic science to clinical practice. Curr Oncol
Rep. 25:63–81. 2023. View Article : Google Scholar
|
|
10
|
Choi H and Hwang W: Anesthetic approaches
and their impact on cancer recurrence and metastasis: A
comprehensive review. Cancers (Basel). 16:42692024. View Article : Google Scholar
|
|
11
|
Santander Ballestín S, Lanuza Bardaji A,
Marco Continente C and Luesma Bartolomé MJ: Antitumor anesthetic
strategy in the perioperatory period of the oncological patient: A
review. Front Med (Lausanne). 9:7993552022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu J, Yang J and Duan J: Anesthetic agents
as therapeutic tools in breast cancer: Insights into cancer
progression and recurrence. Clin Breast Cancer. 25:e561–e576. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sessler DI, Pei L, Huang Y, Fleischmann E,
Marhofer P, Kurz A, Mayers DB, Meyer-Treschan TA, Grady M, Tan EY,
et al: Recurrence of breast cancer after regional or general
anaesthesia: A randomised controlled trial. Lancet. 394:1807–1815.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao SJ, Zhang Y, Zhang YX, Zhao W, Pan LH,
Sun XD, Jia Z, Ouyang W, Ye QS, Zhang FX, et al: Long-term survival
in older patients given propofol or sevoflurane anaesthesia for
major cancer surgery: Follow-up of a multicentre randomised trial.
Br J Anaesth. 131:266–275. 2023. View Article : Google Scholar
|
|
15
|
Bennett-Guerrero E, Romeiser JL, DeMaria
S, Nadler JW, Quinn TD, Ponnappan SK, Wang R, Gloff MS, Lee KJ,
Levin MA, et al: Anesthesia type during cancer surgery: Results of
the GA-CARES randomized, multicenter trial. Anesthesiology.
144:51–62. 2026. View Article : Google Scholar
|
|
16
|
Hiller JG, Perry NJ, Poulogiannis G,
Riedel B and Sloan EK: Perioperative events influence cancer
recurrence risk after surgery. Nat Rev Clin Oncol. 15:205–218.
2018. View Article : Google Scholar
|
|
17
|
Reysner T and Reysner M: Regional
anesthesia and the perioperative inflammatory window in cancer
surgery: From surgical stress to immunometabolic reprogramming.
Cancers (Basel). 18:11582026. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reysner T, Wieczorowska-Tobis K, Kowalski
G, Grochowicka M, Pyszczorska M, Mularski A and Reysner M: The
influence of regional anesthesia on the systemic stress response.
Reports. 7:892024. View Article : Google Scholar
|
|
19
|
Wall TP and Buggy DJ: Perioperative
intravenous lidocaine and metastatic cancer recurrence-A narrative
review. Front Oncol. 11:6888962021. View Article : Google Scholar
|
|
20
|
Sahinovic MM, Struys MMRF and Absalom AR:
Clinical pharmacokinetics and pharmacodynamics of propofol. Clin
Pharmacokinet. 57:1539–1558. 2018. View Article : Google Scholar
|
|
21
|
Sekandarzad MW, van Zundert AAJ, Lirk PB,
Doornebal CW and Hollmann MW: Perioperative anesthesia care and
tumor progression. Anesth Analg. 124:1697–1708. 2017. View Article : Google Scholar
|
|
22
|
Zhou X, Shao Y, Li S, Zhang S, Ding C,
Zhuang L and Sun J: An intravenous anesthetic drug-propofol,
influences the biological characteristics of malignant tumors and
reshapes the tumor microenvironment: A narrative literature review.
Front Pharmacol. 13:10575712022. View Article : Google Scholar :
|
|
23
|
Piegeler T, Schläpfer M, Dull RO, Schwartz
DE, Borgeat A, Minshall RD and Beck-Schimmer B: Clinically relevant
concentrations of lidocaine and ropivacaine inhibit TNFα-induced
invasion of lung adenocarcinoma cells in vitro by blocking the
activation of Akt and focal adhesion kinase. Br J Anaesth.
115:784–791. 2015. View Article : Google Scholar
|
|
24
|
Chamaraux-Tran TN, Mathelin C, Aprahamian
M, Joshi GP, Tomasetto C, Diemunsch P and Akladios C: Antitumor
effects of lidocaine on human breast cancer cells: An in vitro and
in vivo experimental trial. Anticancer Res. 38:95–105. 2018.
|
|
25
|
Zhou R, Konishi Y, Zhang A and Nishiwaki
K: Propofol elicits apoptosis and attenuates cell growth in
esophageal cancer cell lines. Nagoya J Med Sci. 85:579–591.
2023.PubMed/NCBI
|
|
26
|
Lai RC, Shan WR, Zhou D, Zeng XQ, Zuo K,
Pan DF, Zeng WA and Zuo ZY: Sevoflurane promotes migration,
invasion, and colony-forming ability of human glioblastoma cells
possibly via increasing the expression of cell surface protein 44.
Acta Pharmacol Sin. 40:1424–1435. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chamaraux-Tran TN and Piegeler T: The
amide local anesthetic lidocaine in cancer surgery-potential
antimetastatic effects and preservation of immune cell function? A
narrative review. Front Med (Lausanne). 4:2352017. View Article : Google Scholar
|
|
28
|
Murphy L, Shaker J and Buggy DJ:
Anaesthetic techniques and strategies: Do they influence
oncological outcomes? Curr Oncol. 30:5309–5321. 2023. View Article : Google Scholar :
|
|
29
|
D'Agostino G, Saporito A, Cecchinato V,
Silvestri Y, Borgeat A, Anselmi L and Uguccioni M: Lidocaine
inhibits cytoskeletal remodelling and human breast cancer cell
migration. Br J Anaesth. 121:962–968. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu H, Dilger JP and Lin J: Lidocaine
suppresses viability and migration of human breast cancer cells:
TRPM7 as a target for some breast cancer cell lines. Cancers
(Basel). 13:2342021. View Article : Google Scholar
|
|
31
|
Liu C, Yu M, Li Y, Wang H, Xu C, Zhang X,
Li M, Guo H, Ma D and Guo X: Lidocaine inhibits the metastatic
potential of ovarian cancer by blocking NaV 1.5-mediated
EMT and FAK/Paxillin signaling pathway. Cancer Med. 10:337–349.
2021. View Article : Google Scholar :
|
|
32
|
Rizaner N, Fraser SP, Gul IB, Purut E,
Djamgoz MBA and Altun S: Lidocaine inhibits rat prostate cancer
cell invasiveness and voltage-gated sodium channel expression in
plasma membrane. J Membr Biol. 257:17–24. 2024. View Article : Google Scholar
|
|
33
|
Djamgoz MBA, Fraser SP and Brackenbury WJ:
In vivo evidence for voltage-gated sodium channel expression in
carcinomas and potentiation of metastasis. Cancers (Basel).
11:16752019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wall TP, Crowley PD, Sherwin A, Foley AG
and Buggy DJ: Effects of lidocaine and Src inhibition on metastasis
in a murine model of breast cancer surgery. Cancers (Basel).
11:14142019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Patel A, Sabbineni H, Clarke A and
Somanath PR: Novel roles of Src in cancer cell
epithelial-to-mesenchymal transition, vascular permeability,
microinvasion and metastasis. Life Sci. 157:52–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lirk P, Berger R, Hollmann MW and Fiegl H:
Lidocaine time- and dose-dependently demethylates deoxyribonucleic
acid in breast cancer cell lines in vitro. Br J Anaesth.
109:200–207. 2012. View Article : Google Scholar
|
|
37
|
Li K, Yang J and Han X: Lidocaine
sensitizes the cytotoxicity of cisplatin in breast cancer cells via
up-regulation of RARβ2 and RASSF1A demethylation. Int J Mol Sci.
15:23519–23536. 2014. View Article : Google Scholar
|
|
38
|
Hsieh WH, Liao SW, Chan SM, Hou JD, Wu SY,
Ho BY, Chen KY, Tai YT, Fang HW, Fang CY, et al: Lidocaine induces
epithelial-mesenchymal transition and aggravates cancer behaviors
in non-small cell lung cancer A549 cells. Oncol Lett. 26:3462023.
View Article : Google Scholar
|
|
39
|
Xing B, Yang L and Cui Y: Lidocaine
inhibited migration of NSCLCA549 cells via the CXCR4 regulation.
Cancer Biomark. 33:317–330. 2022. View Article : Google Scholar
|
|
40
|
Li R, Xiao C, Liu H, Huang Y, Dilger JP
and Lin J: Effects of local anesthetics on breast cancer cell
viability and migration. BMC Cancer. 18:6662018. View Article : Google Scholar
|
|
41
|
Jiang S, Liu Y, Huang L, Zhang F and Kang
R: Effects of propofol on cancer development and chemotherapy:
Potential mechanisms. Eur J Pharmacol. 831:46–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Buschmann D, Brandes F, Lindemann A,
Maerte M, Ganschow P, Chouker A, Schelling G, Pfaffl MW and
Reithmair M: Propofol and sevoflurane differentially impact
MicroRNAs in circulating extracellular vesicles during colorectal
cancer resection: A pilot study. Anesthesiology. 132:107–120. 2020.
View Article : Google Scholar
|
|
43
|
Chang Q, Wu J, An Y, Liu H and Sun Y:
Propofol suppresses proliferation, migration, invasion, and tumor
growth of liver cancer cells via suppressing cancer susceptibility
candidate 9/phosphatase and tensin homolog/AKT serine/threonine
kinase/mechanistic target of rapamycin kinase axis. Hum Exp
Toxicol. 41:96032712110659722022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang R, Li S, Hou Q, Zhang B, Chu H, Hou
Y, Ni C, Sun L, Ran Y and Zheng H: Propofol inhibits colon cancer
cell stemness and epithelial-mesenchymal transition by regulating
SIRT1, Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways. Discov
Oncol. 14:1372023. View Article : Google Scholar
|
|
45
|
Wang Y, Xu B, Zhou J and Wu X: Propofol
activates AMPK to inhibit the growth of HepG2 cells in vitro and
hepatocarcinogenesis in xenograft mouse tumor models by inducing
autophagy. J Gastrointest Oncol. 11:1322–1332. 2020. View Article : Google Scholar
|
|
46
|
Sun L, Ma W, Gao W, Xing Y, Chen L, Xia Z,
Zhang Z and Dai Z: Propofol directly induces caspase-1-dependent
macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell
Death Dis. 10:5422019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Z, Cao B, Ji P and Yao F: Propofol
inhibits tumor angiogenesis through targeting VEGF/VEGFR and
mTOR/eIF4E signaling. Biochem Biophys Res Commun. 555:13–18. 2021.
View Article : Google Scholar
|
|
48
|
Yang N, Liang Y, Yang P and Ji F: Propofol
suppresses LPS-induced nuclear accumulation of HIF-1α and tumor
aggressiveness in non-small cell lung cancer. Oncol Rep.
37:2611–2619. 2017. View Article : Google Scholar
|
|
49
|
Schito L and Semenza GL: Hypoxia-inducible
factors: Master regulators of cancer progression. Trends Cancer.
2:758–770. 2016. View Article : Google Scholar
|
|
50
|
Lu H, Zheng G, Gao X, Chen C, Zhou M and
Zhang L: Propofol suppresses cell viability, cell cycle progression
and motility and induces cell apoptosis of ovarian cancer cells
through suppressing MEK/ERK signaling via targeting
circVPS13C/miR-145 axis. J Ovarian Res. 14:302021. View Article : Google Scholar
|
|
51
|
Shen X, Wang D, Chen X and Peng J:
Propofol inhibits proliferation, migration, invasion and promotes
apoptosis by regulating HOST2/JAK2/STAT3 signaling pathway in
ovarian cancer cells. Cytotechnology. 73:243–252. 2021. View Article : Google Scholar
|
|
52
|
Gao M, Guo R, Lu X, Xu G and Luo S:
Propofol suppresses hypoxia-induced esophageal cancer cell
migration, invasion, and EMT through regulating lncRNA
TMPO-AS1/miR-498 axis. Thorac Cancer. 11:2398–2405. 2020.
View Article : Google Scholar
|
|
53
|
Fan X, Gong M, Yu H, Yang H, Wang S and
Wang R: Propofol enhances stem-like properties of glioma via
GABAAR-dependent Src modulation of ZDHHC5-EZH2
palmitoylation mechanism. Stem Cell Res Ther. 13:3982022.
View Article : Google Scholar
|
|
54
|
Benzonana LL, Perry NJS, Watts HR, Yang B,
Perry IA, Coombes C, Takata M and Ma D: Isoflurane, a commonly used
volatile anesthetic, enhances renal cancer growth and malignant
potential via the hypoxia-inducible factor cellular signaling
pathway in vitro. Anesthesiology. 119:593–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang H, Benzonana LL, Zhao H, Watts HR,
Perry NJ, Bevan C, Brown R and Ma D: Prostate cancer cell
malignancy via modulation of HIF-1α pathway with isoflurane and
propofol alone and in combination. Br J Cancer. 111:1338–1349.
2014. View Article : Google Scholar
|
|
56
|
Ishikawa M, Iwasaki M, Zhao H, Saito J, Hu
C, Sun Q, Sakamoto A and Ma D: Inhalational anesthetics inhibit
neuroglioma cell proliferation and migration via miR-138, -210 and
-335. Int J Mol Sci. 22:43552021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhao H, Xing F, Yuan J, Li Z and Zhang W:
Sevoflurane inhibits migration and invasion of glioma cells via
regulating miR-34a-5p/MMP-2 axis. Life Sci. 256:1178972020.
View Article : Google Scholar
|
|
58
|
Scroope CA, Singleton Z, Hollmann MW and
Parat MO: Opioid receptor-mediated and non-opioid receptor-mediated
roles of opioids in tumour growth and metastasis. Front Oncol.
11:7922902021. View Article : Google Scholar
|
|
59
|
Zhou Y, Li W, Chen Y, Hu X and Miao C:
Research progress on the impact of opioids on the tumor immune
microenvironment (review). Mol Clin Oncol. 22:532025. View Article : Google Scholar
|
|
60
|
Wang Z, Jiang L, Wang J, Chai Z and Xiong
W: Morphine promotes angiogenesis by activating PI3K/Akt/HIF-1α
pathway and upregulating VEGF in hepatocellular carcinoma. J
Gastrointest Oncol. 12:1761–1772. 2021. View Article : Google Scholar
|
|
61
|
Zhang H, Zhou D, Gu J, Qu M, Guo K, Chen W
and Miao C: Targeting the mu-opioid receptor for cancer treatment.
Curr Oncol Rep. 23:1112021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ramirez MF, Strang A, Roland G, Lasala J
and Owusu-Agyemang P: Perioperative pain management and cancer
outcomes: A narrative review. J Pain Res. 16:4181–4189. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang K, Wu M, Xu J, Wu C, Zhang B, Wang G
and Ma D: Effects of dexmedetomidine on perioperative stress,
inflammation, and immune function: Systematic review and
meta-analysis. Br J Anaesth. 123:777–794. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yuki K: The immunomodulatory mechanism of
dexmedetomidine. Int Immunopharmacol. 97:1077092021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jun JH, Shim JK, Oh JE, Kim KS, Kwak YL
and Soh S: Effects of dexmedetomidine on A549 non-small cell lung
cancer growth in a clinically relevant surgical xenograft model.
Sci Rep. 13:124712023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang C, Qu Y, Cao Q, Tao Y, Huai X, Xuan
W, Pan Z, Wang X and Tian J: Effect of intraoperative
dexmedetomidine on prognosis in patients with cancer undergoing
surgical procedures: A systematic review and meta-analysis. Br J
Anaesth. 135:89–98. 2025. View Article : Google Scholar
|
|
67
|
Bied M, Ho WW, Ginhoux F and Blériot C:
Roles of macrophages in tumor development: A spatiotemporal
perspective. Cell Mol Immunol. 20:983–992. 2023. View Article : Google Scholar :
|
|
68
|
Yaniv D, Mattson B, Talbot S, Gleber-Netto
FO and Amit M: Targeting the peripheral neural-tumour
microenvironment for cancer therapy. Nat Rev Drug Discov.
23:780–796. 2024. View Article : Google Scholar
|
|
69
|
Bezu L, Wu Chuang A, Sauvat A, Humeau J,
Xie W, Cerrato G, Liu P, Zhao L, Zhang S, Le Naour J, et al: Local
anesthetics elicit immune-dependent anticancer effects. J
Immunother Cancer. 10:e0041512022. View Article : Google Scholar :
|
|
70
|
Ramirez MF, Tran P and Cata JP: The effect
of clinically therapeutic plasma concentrations of lidocaine on
natural killer cell cytotoxicity. Reg Anesth Pain Med. 40:43–48.
2015. View Article : Google Scholar
|
|
71
|
Cata JP, Ramirez MF, Velasquez JF, Di AI,
Popat KU, Gottumukkala V, Black DM, Lewis VO and Vauthey JN:
Lidocaine stimulates the function of natural killer cells in
different experimental settings. Anticancer Res. 37:4727–4732.
2017.
|
|
72
|
Wu YY, Chen MS, Chen IC, Wu FH, Liao TL,
Wen HW, Nielsen BL and Liu HJ: Lidocaine modulates cytokine
production and reprograms the tumor immune microenvironment to
enhance anti-tumor immune responses in gastric cancer. Int J Mol
Sci. 26:32362025. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lim JA, Oh CS, Yoon TG, Lee JY, Lee SH,
Yoo YB, Yang JH and Kim SH: The effect of propofol and sevoflurane
on cancer cell, natural killer cell, and cytotoxic T lymphocyte
function in patients undergoing breast cancer surgery: An in vitro
analysis. BMC Cancer. 18:1592018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Buckley A, McQuaid S, Johnson P and Buggy
DJ: Effect of anaesthetic technique on the natural killer cell
anti-tumour activity of serum from women undergoing breast cancer
surgery: A pilot study. Br J Anaesth. 113(Suppl 1): i56–i62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Apisutimaitri K, Saeyup P, Suppipat K,
Sirichindakul P, Wanasrisant N, Nonsri C and Lertprapai P: Effects
of propofol-based total intravenous anesthesia versus desflurane
anesthesia on natural killer cell cytotoxicity after hepatocellular
carcinoma resection. J Anaesthesiol Clin Pharmacol. 40:395–402.
2024. View Article : Google Scholar
|
|
76
|
Gao J, Hu H and Wang X: Clinically
relevant concentrations of lidocaine inhibit tumor angiogenesis
through suppressing VEGF/VEGFR2 signaling. Cancer Chemother
Pharmacol. 83:1007–1015. 2019. View Article : Google Scholar
|
|
77
|
Cole SW and Sood AK: Molecular pathways:
Beta-adrenergic signaling in cancer. Clin Cancer Res. 18:1201–1206.
2012. View Article : Google Scholar
|
|
78
|
Thaker PH, Han LY, Kamat AA, Arevalo JM,
Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori
M, et al: Chronic stress promotes tumor growth and angiogenesis in
a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006.
View Article : Google Scholar
|
|
79
|
Sloan EK, Priceman SJ, Cox BF, Yu S,
Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas
BD, Wu L, et al: The sympathetic nervous system induces a
metastatic switch in primary breast cancer. Cancer Res.
70:7042–7052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Haldar R, Ricon-Becker I, Radin A, Gutman
M, Cole SW, Zmora O and Ben-Eliyahu S: Perioperative COX2 and
β-adrenergic blockade improves biomarkers of tumor metastasis,
immunity, and inflammation in colorectal cancer: A randomized
controlled trial. Cancer. 126:3991–4001. 2020. View Article : Google Scholar
|
|
81
|
Shaashua L, Shabat-Simon M, Haldar R,
Matzner P, Zmora O, Shabtai M, Sharon E, Allweis T, Barshack I,
Hayman L, et al: Perioperative COX-2 and β-adrenergic blockade
improves metastatic biomarkers in breast cancer patients in a
phase-II randomized trial. Clin Cancer Res. 23:4651–4661. 2017.
View Article : Google Scholar
|
|
82
|
Haldar R, Shaashua L, Lavon H, Lyons YA,
Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, et
al: Perioperative inhibition of β-adrenergic and COX2 signaling in
a clinical trial in breast cancer patients improves tumor Ki-67
expression, serum cytokine levels, and PBMCs transcriptome. Brain
Behav Immun. 73:294–309. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ripollés-Melchor J, Abad-Motos A and
Zorrilla-Vaca A: Enhanced recovery after surgery (ERAS) in surgical
oncology. Curr Oncol Rep. 24:1177–1187. 2022. View Article : Google Scholar
|
|
84
|
Lee ZX, Ng KT, Ang E, Wang CY and Binti
Shariffuddin IIB: Effect of perioperative regional anesthesia on
cancer recurrence: A meta-analysis of randomized controlled trials.
Int J Surg. 82:192–199. 2020. View Article : Google Scholar
|
|
85
|
Badwe RA, Parmar V, Nair N, Joshi S,
Hawaldar R, Pawar S, Kadayaprath G, Borthakur BB, Rao Thammineedi
S, Pandya S, et al: Effect of peritumoral infiltration of local
anesthetic before surgery on survival in early breast cancer. J
Clin Oncol. 41:3318–3328. 2023. View Article : Google Scholar
|
|
86
|
Zheng Q, Peng X and Zhang Y: Cytotoxicity
of amide-linked local anesthetics on melanoma cells via inhibition
of Ras and RhoA signaling independent of sodium channel blockade.
BMC Anesthesiol. 20:432020. View Article : Google Scholar :
|
|
87
|
Xu P, Zhang S, Tan L, Wang L, Yang Z and
Li J: Local anesthetic ropivacaine exhibits therapeutic effects in
cancers. Front Oncol. 12:8368822022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Xuan W, Zhao H, Hankin J, Chen L, Yao S
and Ma D: Local anesthetic bupivacaine induced ovarian and prostate
cancer apoptotic cell death and underlying mechanisms in vitro. Sci
Rep. 6:262772016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wang S, Li M, Cai S and Zhang W:
Transcriptome analysis reveals the differential inflammatory
effects between propofol and sevoflurane during lung cancer
resection: A randomized pilot study. World J Surg Oncol. 21:82023.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li Y, Sun L, Zhou Q, Lee AJ, Wang L, Zhang
R and Wang S: Effects of opioid drugs on immune function in cancer
patients. Biomed Pharmacother. 175:1166652024. View Article : Google Scholar
|
|
91
|
Klein JA and Jeske DR: Estimated maximal
safe dosages of tumescent lidocaine. Anesth Analg. 122:1350–1359.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Toner AJ, Bailey MA, Schug SA and Corcoran
TB: A pilot multicentre randomised controlled trial of lidocaine
infusion in women undergoing breast cancer surgery. Anaesthesia.
76:1326–1341. 2021. View Article : Google Scholar
|
|
93
|
Toner AJ, Bailey MA, Schug SA, Phillips M,
Ungerer JPJ, Somogyi AA and Corcoran TB: Serum lidocaine
(lignocaine) concentrations during prolonged perioperative infusion
in patients undergoing breast cancer surgery: A secondary analysis
of a randomised controlled trial. Anaesth Intensive Care.
51:422–431. 2023. View Article : Google Scholar
|
|
94
|
Greenwood E, Nimmo S, Paterson H, Homer N
and Foo I: Intravenous lidocaine infusion as a component of
multimodal analgesia for colorectal surgery-measurement of plasma
levels. Perioper Med (Lond). 8:12019. View Article : Google Scholar
|
|
95
|
Chhabra D, Bhatia P, Sethi P, Kaloria N,
Kumar M and Kaur M: To ascertain the plasma concentration of
propofol to achieve bispectral index-guided sedation using a
target-controlled infusion in patients undergoing elective
surgeries under neuraxial anaesthesia. Indian J Anaesth.
66:832–836. 2022. View Article : Google Scholar
|
|
96
|
Mazoit JX and Samii K: Binding of propofol
to blood components: Implications for pharmacokinetics and for
pharmacodynamics. Br J Clin Pharmacol. 47:35–42. 1999. View Article : Google Scholar
|
|
97
|
Colonna G: Overcoming barriers in cancer
biology research: Current limitations and solutions. Cancers
(Basel). 17:21022025. View Article : Google Scholar :
|
|
98
|
Olson B, Li Y, Lin Y, Liu ET and Patnaik
A: Mouse models for cancer immunotherapy research. Cancer Discov.
8:1358–1365. 2018. View Article : Google Scholar
|
|
99
|
Yang Y, Cui J, Kong Y, Hou Y and Ma C:
Organoids: New frontiers in tumor immune microenvironment research.
Front Immunol. 15:14220312024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Tang Y, Tang L, Yao Y, Huang H and Chen B:
Effects of anesthesia on long-term survival in cancer surgery: A
systematic review and meta-analysis. Heliyon. 10:e247912024.
View Article : Google Scholar
|
|
101
|
Polak R, Zhang ET and Kuo CJ: Cancer
organoids 2.0: Modelling the complexity of the tumour immune
microenvironment. Nat Rev Cancer. 24:523–539. 2024. View Article : Google Scholar
|
|
102
|
Yang R and Yu Y: Patient-derived organoids
in translational oncology and drug screening. Cancer Lett.
562:2161802023. View Article : Google Scholar
|
|
103
|
Wang D, Villenave R, Stokar-Regenscheit N
and Clevers H: Human organoids as 3D in vitro platforms for drug
discovery: Opportunities and challenges. Nat Rev Drug Discov.
25:204–226. 2026. View Article : Google Scholar
|
|
104
|
Liu X, Fang J, Huang S, Wu X, Xie X, Wang
J, Liu F, Zhang M, Peng Z and Hu N: Tumor-on-a-chip: From
bioinspired design to biomedical application. Microsyst Nanoeng.
7:502021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ayuso JM, Rehman S, Virumbrales-Munoz M,
McMinn PH, Geiger P, Fitzgerald C, Heaster T, Skala MC and Beebe
DJ: Microfluidic tumor-on-a-chip model to evaluate the role of
tumor environmental stress on NK cell exhaustion. Sci Adv.
7:eabc23312021. View Article : Google Scholar :
|
|
106
|
Xiao J, Yu X, Meng F, Zhang Y, Zhou W, Ren
Y, Li J, Sun Y, Sun H, Chen G, et al: Integrating spatial and
single-cell transcriptomics reveals tumor heterogeneity and
intercellular networks in colorectal cancer. Cell Death Dis.
15:3262024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T,
Fu X, Yao X and Peng Y: Advances in spatial transcriptomics and its
applications in cancer research. Mol Cancer. 23:1292024. View Article : Google Scholar :
|
|
108
|
Janesick A, Shelansky R, Gottscho AD,
Wagner F, Williams SR, Rouault M, Beliakoff G, Morrison CA,
Oliveira MF, Sicherman JT, et al: High resolution mapping of the
tumor microenvironment using integrated single-cell, spatial and in
situ analysis. Nat Commun. 14:83532023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Du Y, Shi J, Wang J, Xun Z, Yu Z, Sun H,
Bao R, Zheng J, Li Z and Ye Y: Integration of pan-cancer
single-cell and spatial transcriptomics reveals stromal cell
features and therapeutic targets in tumor microenvironment. Cancer
Res. 84:192–210. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Lei W, Zhou K, Lei Y, Li Q and Zhu H: Gut
microbiota shapes cancer immunotherapy responses. NPJ Biofilms
Microbiomes. 11:1432025. View Article : Google Scholar
|
|
111
|
Jiang N, Wang L, Chen X and Yu C:
Interactions between perioperative anesthesia management and gut
microbiota: Current research advances. Cell Mol Neurobiol.
46:672026. View Article : Google Scholar
|
|
112
|
Bell M, Buggy DJ, Brattström D, Buchli C,
Debouche S, Granath F, Riedel B and Gupta A: The effects of
anaesthesia and analgesia on short- and long-term outcomes
following colorectal cancer surgery: Protocol for an international,
pragmatic, cohort study (ENCORE). Eur J Anaesthesiol Intensive
Care. 3:e00512024. View Article : Google Scholar
|
|
113
|
Huang Q, Zhou R, Hao X, Zhang W, Chen G
and Zhu T: Circulating biomarkers in perioperative management of
cancer patients. Precis Clin Med. 6:pbad0182023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Efthymiou V, Queenan N, Haas M, Naegele S,
Goss D and Faden DL: Circulating tumor DNA in the immediate
postoperative setting. Ann Surg Oncol. 31:2319–2325. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dai CS, Mishra A, Edd J, Toner M,
Maheswaran S and Haber DA: Circulating tumor cells: Blood-based
detection, molecular biology, and clinical applications. Cancer
Cell. 43:1399–1422. 2025. View Article : Google Scholar
|
|
116
|
Henriksen TV, Reinert T, Christensen E,
Sethi H, Birkenkamp-Demtröder K, Gögenur M, Gögenur I, Zimmermann
BG; IMPROVE Study Group; Dyrskjøt L and Andersen CL: The effect of
surgical trauma on circulating free DNA levels in cancer
patients-implications for studies of circulating tumor DNA. Mol
Oncol. 14:1670–1679. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Bezu L, Kepp O and Kroemer G: Local
anesthetics and immunotherapy: A novel combination to fight cancer.
Semin Immunopathol. 45:265–272. 2023. View Article : Google Scholar
|
